Article
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study
24 Apr 2025
Abstract excerpt
BACKGROUND: In Spain, next-generation sequencing (NGS) is currently available in a limited number of specialized centers and remains inaccessible to a significant proportion of patients. The ATLAS study aims to explore the tumor molecular profile beyond known EGFR mutations and ALK translocations using NGS on tumor biopsy samples. METHODS: Patients with EGFR-sensitizing mutations or ALK translocations were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
